ZA200201511B - 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents. - Google Patents

3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.

Info

Publication number: ZA200201511B
Authority: ZA; South Africa
Prior art keywords: amino; preparation; antitumor agents; pyrazole derivatives; pyrazole
Prior art date: 1999-08-12

Application number

ZA200201511A

Other languages

English (en)

Inventor

Paolo Pevarello

Paolo Orsini

Gabriella Traquandi

Mario Varasi

Edward L Fritzen

Martha A Warpehoski

Betsy S Pierce

Maria Grabriella Brasca

Original Assignee

Pharmacia Italia Spa

Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-12

Filing date

2002-02-22

Publication date

2003-05-28

2002-02-22 Application filed by Pharmacia Italia Spa, Upjohn Co filed Critical Pharmacia Italia Spa

2003-05-28 Publication of ZA200201511B publication Critical patent/ZA200201511B/xx

Links

JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Virology (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ZA200201511A 1999-08-12 2002-02-22 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents. ZA200201511B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37283199A	1999-08-12	1999-08-12

Publications (1)

Publication Number	Publication Date
ZA200201511B true ZA200201511B (en)	2003-05-28

Family

ID=23469802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200201511A ZA200201511B (en)	1999-08-12	2002-02-22	3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.

Country Status (35)

Country	Link
US (2)	US7034049B1 (de)
EP (1)	EP1202733B1 (de)
JP (1)	JP2003507329A (de)
KR (1)	KR20020060160A (de)
CN (1)	CN1373662A (de)
AP (1)	AP2002002442A0 (de)
AR (1)	AR026122A1 (de)
AT (1)	ATE305782T1 (de)
AU (1)	AU4971400A (de)
BG (1)	BG106480A (de)
BR (1)	BR0013143A (de)
CA (1)	CA2383555C (de)
CZ (1)	CZ2002422A3 (de)
DE (1)	DE60023012T2 (de)
DK (1)	DK1202733T3 (de)
EA (1)	EA005373B1 (de)
EE (1)	EE200200065A (de)
ES (1)	ES2249270T3 (de)
GE (1)	GEP20053476B (de)
HK (1)	HK1046866A1 (de)
HR (1)	HRP20020128A2 (de)
HU (1)	HUP0203542A3 (de)
IL (1)	IL147923A0 (de)
IS (1)	IS6265A (de)
MA (1)	MA25493A1 (de)
MX (1)	MXPA02001498A (de)
NO (1)	NO20020684L (de)
NZ (1)	NZ517237A (de)
OA (1)	OA12046A (de)
PE (1)	PE20010130A1 (de)
PL (1)	PL353455A1 (de)
SK (1)	SK1812002A3 (de)
WO (1)	WO2001012189A1 (de)
YU (1)	YU9602A (de)
ZA (1)	ZA200201511B (de)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901691D0 (en)	1999-01-26	1999-03-17	Cerebrus Ltd	Chemical compounds
CN1373662A (zh) *	1999-08-12	2002-10-09	法玛西雅意大利公司	3(5)－氨基－吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途
JP2003522174A (ja)	2000-02-07	2003-07-22	ブリストル−マイヤーズスクイブカンパニー	サイクリン依存性キナーゼの３−アミノピラゾール阻害剤
JP2004507455A (ja)	2000-04-25	2004-03-11	ブリストル−マイヤーズ　スクイブ　カンパニー	サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途
DE10037310A1 (de)	2000-07-28	2002-02-07	Asta Medica Ag	Neue Indolderivate und deren Verwendung als Arzneimittel
SK2002003A3 (en) *	2000-08-31	2004-04-06	Pfizer Prod Inc	Pyrazole derivatives and their use as protein kinase inhibitors
US20020103185A1 (en) *	2000-08-31	2002-08-01	Sanner Mark A.	Pyrazole derivatives
US6455559B1 (en) *	2001-07-19	2002-09-24	Pharmacia Italia S.P.A.	Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
AU2002215053A1 (en) *	2000-11-27	2002-06-24	Pharmacia Italia S.P.A.	Phenylacetamido- pyrazole derivatives and their use as antitumor agents
WO2002070515A2 (en) *	2001-01-26	2002-09-12	Pharmacia Italia Spa	Chromane derivatives, process for their preparation and their use as antitumor agents
JP2004526721A (ja) *	2001-03-02	2004-09-02	エフ．ホフマン−ラ　ロシュ　アーゲー	Ｉｐアンタゴニストとしてのアルコキシカルボニルアミノヘテロアリールカルボン酸誘導体
SE0100903D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
SE0100902D0 (sv) *	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
US6787555B2 (en) *	2001-04-30	2004-09-07	The Procter & Gamble Company	Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en)	2001-04-30	2004-04-27	The Procter & Gamble Company	Triazole compounds useful in treating diseases associated with unwanted cytokine activity
ATE445400T1 (de)	2001-05-25	2009-10-15	Bristol Myers Squibb Co	Hydantion-derivate als hemmer von matrix- metalloproteinasen
DE10148617A1 (de) *	2001-09-25	2003-04-24	Schering Ag	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148618B4 (de) *	2001-09-25	2007-05-03	Schering Ag	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
ATE440094T1 (de) *	2001-09-27	2009-09-15	Equispharm Co Ltd	Fumagillolderivate und verfahren zu deren herstellung
SE0103710D0 (sv)	2001-11-07	2001-11-07	Astrazeneca Ab	Compounds
AU2002362030A1 (en) *	2001-11-27	2003-06-10	Fred Hutchinson Cancer Research Center	Methods for inhibiting deacetylase activity
SE0202539D0 (sv)	2002-08-27	2002-08-27	Astrazeneca Ab	Compounds
GB0221246D0 (en) *	2002-09-13	2002-10-23	Astrazeneca Ab	Compounds
US6593477B1 (en)	2002-10-29	2003-07-15	Eastman Kodak Company	Synthesis of 3-acylaminopyrazoles
NZ540799A (en) *	2002-12-10	2008-09-26	Virochem Pharma Inc	Compounds and methods for the treatment or prevention of flavivirus infections
UA81790C2 (uk)	2002-12-19	2008-02-11	Фармация Италия С.П.А.	Заміщені піролопіразольні похідні як інгібітори кінази
AU2003294376A1 (en) *	2003-01-06	2004-08-10	Eli Lilly And Company	Heteroaryl compounds
PL378117A1 (pl) *	2003-02-11	2006-03-06	Prosidion Limited	Tricyklopodstawione związki amidowe
JP2006524239A (ja) *	2003-03-27	2006-10-26	メルク　エンド　カムパニー　インコーポレーテッド	高眼圧症を治療するための眼用組成物
SE0301446D0 (sv)	2003-05-16	2003-05-16	Astrazeneca Ab	New Compounds
GEP20094664B (en)	2003-05-22	2009-04-10	Nerviano Medical Sciences Srl	Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
JP4220548B2 (ja)	2003-06-05	2009-02-04	エランファーマシューティカルズ，インコーポレイテッド	アシル化されたアミノ酸・アミジルピラゾール、および関連化合物
US7141568B2 (en)	2003-07-09	2006-11-28	Pfizer Italia S.R.L.	Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2004270733B2 (en)	2003-09-11	2011-05-19	Itherx Pharma, Inc.	Cytokine inhibitors
ATE443701T1 (de) *	2004-01-16	2009-10-15	Wyeth Corp	Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
WO2005072731A1 (en) *	2004-01-29	2005-08-11	X-Ceptor Therapeutics, Inc.	3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
WO2005075435A1 (en)	2004-01-30	2005-08-18	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
TW200526204A (en)	2004-02-03	2005-08-16	Pharmacia Italia Spa	1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2005118543A1 (ja) *	2004-06-03	2005-12-15	Ono Pharmaceutical Co., Ltd.	キナーゼ阻害薬およびその用途
US7648992B2 (en)	2004-07-05	2010-01-19	Astrazeneca Ab	Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) *	2004-07-05	2004-07-05	Astrazeneca Ab	Novel compounds
CA2590720A1 (en) *	2004-12-03	2006-06-08	Lone Jeppesen	Heteroaromatic glucokinase activators
SE0403086D0 (sv)	2004-12-17	2004-12-17	Astrazeneca Ab	Compounds
SE0403085D0 (sv)	2004-12-17	2004-12-17	Astrazeneca Ab	Novel componds
US7361672B2 (en)	2004-12-23	2008-04-22	Hoffmann-La Roche Inc.	Heteroarylacetamide inhibitors of factor Xa
FR2880540B1 (fr) *	2005-01-13	2008-07-11	Aventis Pharma Sa	Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
CA2613303C (en) *	2005-07-11	2012-06-19	Mitsubishi Tanabe Pharma Corporation	An oxime derivative for use as a glucokinase activator
JP5303271B2 (ja)	2005-07-19	2013-10-02	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物
KR20080090381A (ko) *	2005-08-29	2008-10-08	제라드 엠. 하우지	테라뮤틴 조절물질
TW200736227A (en)	2005-12-23	2007-10-01	Astrazeneca Ab	New compounds III
US20070203224A1 (en) *	2006-01-09	2007-08-30	University Of Southern California	Small-molecules for treating cancer and abnormal cell proliferation disorders
WO2007095383A2 (en) *	2006-02-15	2007-08-23	Myriad Genetics, Inc.	Prodrugs
UY30183A1 (es) *	2006-03-02	2007-10-31	Astrazeneca Ab	Derivados de quinolina
US8211925B2 (en)	2006-04-28	2012-07-03	Transtech Pharma, Inc.	Benzamide glucokinase activators
WO2007129052A1 (en) *	2006-05-03	2007-11-15	Astrazeneca Ab	Pyrazole derivatives and their use as pi3k inhibitors
JP2009543768A (ja) *	2006-07-14	2009-12-10	アステックス・セラピューティクス・リミテッド	医薬組み合わせ
TWI433839B (zh)	2006-08-11	2014-04-11	Neomed Inst	新穎的苯并咪唑衍生物290
TW200831488A (en) *	2006-11-29	2008-08-01	Astrazeneca Ab	Novel compounds
US7737149B2 (en)	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008084873A1 (ja) *	2007-01-10	2008-07-17	Mitsubishi Tanabe Pharma Corporation	オキシム誘導体
US8314247B2 (en) *	2007-01-10	2012-11-20	Mitsubishi Tanabe Pharma Corporation	Hydrazone derivative
US8940900B2 (en)	2007-02-28	2015-01-27	Advinus Therapeutics Private Limited	2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
KR100923540B1 (ko) *	2007-11-23	2009-10-27	한국과학기술연구원	5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
CN102123989A (zh) *	2008-06-19	2011-07-13	阿斯利康(瑞典)有限公司	吡唑化合物436
US8466290B2 (en) *	2008-07-10	2013-06-18	Pharma Ip General Incorporated Association	STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient
ES2415907T3 (es)	2008-07-24	2013-07-29	Nerviano Medical Sciences S.R.L.	Combinación terapéutica que comprende un inhibidor de cinasas aurora y agentes antiproliferativos
US20100160322A1 (en)	2008-12-04	2010-06-24	Abbott Laboratories	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en)	2008-12-04	2013-10-15	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en)	2008-12-05	2013-10-22	Abbvie Inc.	Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en)	2008-12-05	2013-11-19	Abbvie Inc.	BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PT2376480T (pt) *	2008-12-05	2016-10-26	Abbvie Inc	Derivados de sulfonamida como agentes indutores de apoptose seletivos de bcl-2 para o tratamento do cancro e de doenças imunes
PE20120003A1 (es) *	2009-01-30	2012-02-12	Glaxosmithkline Llc	Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
US20120045459A1 (en) *	2009-05-05	2012-02-23	Van Andel Research Institute	Methods for Treating Autophagy-Related Disorders
EP2467137A1 (de) *	2009-08-19	2012-06-27	Ambit Biosciences Corporation	Biarylverbindungen und anwendungsverfahren dafür
EP2947073B1 (de) *	2009-10-22	2019-04-03	Fibrotech Therapeutics Pty Ltd	Analoga von antifibriotischen mitteln mit kondensierten ringen
EP2496231A1 (de) *	2009-11-05	2012-09-12	Lexicon Pharmaceuticals, Inc.	Tryptophanhydroxylasehemmer zur behandlung von krebs
EP2560966B1 (de)	2010-03-30	2021-01-06	Verseon International Corporation	Mehrfach substituierte aromatische verbindungen als thrombinhemmer
AU2011265047B2 (en)	2010-06-07	2014-10-23	Novomedix, Llc	Furanyl compounds and the use thereof
WO2011158108A2 (en)	2010-06-16	2011-12-22	Purdue Pharma L.P.	Aryl substituted indoles and the use thereof
ES2775125T3 (es) *	2010-11-03	2020-07-23	Dow Agrosciences Llc	Composiciones plaguicidas y procedimientos relacionados
US9073895B2 (en) *	2010-12-16	2015-07-07	Boehringer Ingelheim International Gmbh	Biarylamide inhibitors of leukotriene production
KR101913441B1 (ko)	2010-12-17	2018-10-30	네르비아노 메디칼 사이언시스 에스.알.엘.	키나제 억제제로서 치환된 피라졸로-퀴나졸린 유도체
FR2978441A1 (fr) *	2011-07-25	2013-02-01	Diverchim	Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
AR087701A1 (es) *	2011-08-31	2014-04-09	Japan Tobacco Inc	Derivados de pirazol con actividad inhibidora de sglt1
EP2755652B1 (de) *	2011-09-16	2021-06-02	Novartis AG	N-substituierte heterocyclische carboxamide
US8937083B2 (en)	2011-10-26	2015-01-20	DowAgroSciences, LLC	Pesticidal compositions and processes related thereto
MA37572B1 (fr)	2012-04-27	2017-10-31	Dow Agrosciences Llc	Compositions pesticides et procédés correspondants
US9708288B2 (en)	2012-04-27	2017-07-18	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US9282739B2 (en)	2012-04-27	2016-03-15	Dow Agrosciences Llc	Pesticidal compositions and processes related thereto
US20140179712A1 (en)	2012-12-21	2014-06-26	Astrazeneca Ab	Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN103936637B (zh) *	2013-01-18	2016-04-06	北京大学	E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用
LT2968297T (lt)	2013-03-15	2019-01-10	Verseon Corporation	Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai
AU2014229233B2 (en)	2013-03-15	2016-08-11	Glaxosmithkline Intellectual Property Development Limited	Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors
AR095308A1 (es)	2013-03-15	2015-10-07	Glaxosmithkline Ip Dev Ltd	Compuesto de 2-piridona, composición farmacéutica que lo comprende y su uso para preparar un medicamento
EP2970141B1 (de)	2013-03-15	2020-02-26	Verseon Corporation	Halogenpyrazole als thrombinhemmer
WO2014170350A1 (en) *	2013-04-17	2014-10-23	Albert Ludwigs Universität Freiburg	Compounds for use as bromodomain inhibitors
CN103265535B (zh) *	2013-05-14	2015-06-17	浙江医药高等专科学校	抗肿瘤化合物、其制备方法和用途
RU2016111675A (ru) *	2013-08-30	2017-10-04	Эмбит Байосайенсиз Корпорейшн	Соединения биарилацетамида и способы их применения
CN105636440A (zh)	2013-10-17	2016-06-01	美国陶氏益农公司	制备杀虫化合物的方法
WO2015058020A1 (en)	2013-10-17	2015-04-23	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
US9102655B2 (en)	2013-10-17	2015-08-11	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
MX2016004940A (es)	2013-10-17	2016-06-28	Dow Agrosciences Llc	Proceso para la preparacion de compuestos plaguicidas.
MX2016004941A (es)	2013-10-17	2016-06-28	Dow Agrosciences Llc	Proceso para la preparacion de compuestos plaguicidas.
CN105636441B (zh)	2013-10-17	2018-06-15	美国陶氏益农公司	制备杀虫化合物的方法
WO2015058023A1 (en)	2013-10-17	2015-04-23	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
TW201519775A (zh)	2013-10-22	2015-06-01	Dow Agrosciences Llc	協同性殺蟲組成物及相關方法（七）
NZ719754A (en)	2013-10-22	2017-06-30	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
JP2016534068A (ja)	2013-10-22	2016-11-04	ダウアグロサイエンシィズエルエルシー	相乗的有害生物防除組成物および関連する方法
RU2656894C2 (ru)	2013-10-22	2018-06-07	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Пестицидные композиции и соответствующие способы
KR20160077113A (ko)	2013-10-22	2016-07-01	다우 아그로사이언시즈 엘엘씨	살충 조성물 및 관련 방법
JP2016538266A (ja)	2013-10-22	2016-12-08	ダウアグロサイエンシィズエルエルシー	相乗的有害生物防除組成物および関連する方法
NZ719634A (en)	2013-10-22	2017-09-29	Dow Agrosciences Llc	Pesticidal compositions and related methods
EP3094183A4 (de)	2013-10-22	2017-08-09	Dow AgroSciences LLC	Synergistische pestizidzusammensetzungen und zugehörige verfahren
TW201519778A (zh)	2013-10-22	2015-06-01	Dow Agrosciences Llc	協同性殺蟲組成物及相關方法（十）
US9295258B2 (en)	2013-10-22	2016-03-29	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
EP3060043A4 (de)	2013-10-22	2017-04-12	Dow AgroSciences, LLC	Pestizidzusammensetzungen und zugehörige verfahren
EP3060042A4 (de)	2013-10-22	2017-04-26	Dow AgroSciences LLC	Synergistische pestizidzusammensetzungen und zugehörige verfahren
RU2016119553A (ru)	2013-10-22	2017-12-04	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Синергетические пестицидные композиции и связанные с ними способы
AU2014340430B2 (en)	2013-10-22	2017-05-25	Dow Agrosciences Llc	Pesticidal compositions and related methods
RU2016119530A (ru)	2013-10-22	2017-11-28	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Синергетические пестицидные композиции и относящиеся к ним способы
AU2014340424B2 (en)	2013-10-22	2017-06-29	Dow Agrosciences Llc	Pesticidal compositions and related methods
WO2015061142A1 (en)	2013-10-22	2015-04-30	Dow Agrosciences Llc	Synergistic pesticidal compositions and related methods
WO2015143653A1 (en)	2014-03-26	2015-10-01	Merck Sharp & Dohme Corp.	TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
CA2954631A1 (en)	2014-07-31	2016-02-04	Dow Agrosciences Llc	Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
US9029555B1 (en)	2014-07-31	2015-05-12	Dow Agrosciences Llc	Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
US9029556B1 (en)	2014-07-31	2015-05-12	Dow Argosciences Llc	Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
CA2958058A1 (en)	2014-08-19	2016-02-25	Dow Agrosciences Llc	Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
CR20170094A (es)	2014-09-10	2017-05-08	Glaxosmithkline Ip Dev Ltd	Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
SG11201701694QA (en)	2014-09-10	2017-04-27	Glaxosmithkline Ip Dev Ltd	Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
KR20170058388A (ko)	2014-09-12	2017-05-26	다우 아그로사이언시즈 엘엘씨	3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
CA2960790A1 (en)	2014-09-17	2016-03-24	Verseon Corporation	Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
GB201416513D0 (en)	2014-09-18	2014-11-05	Astex Therapeutics Ltd And Cancer Res Technology Ltd	Pharmaceutical compounds
EP3261639B1 (de)	2015-02-27	2022-08-24	Verseon International Corporation	Substituierte pyrazolylverbindungen als serinproteaseinhibitoren
EP3268000B1 (de)	2015-03-09	2021-08-04	Aurigene Discovery Technologies Limited	Pyrazolo[1,5-a][1,3,5]triazin- und pyrazolo[1,5-a]pyrimidin-derivate als cdk-inhibitoren
KR20180017013A (ko)	2015-05-06	2018-02-20	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	K-Ras 조절제
KR20180041112A (ko)	2015-06-04	2018-04-23	오리진 디스커버리 테크놀로지스 리미티드	Cdk 억제제로서의 치환된 헤테로사이클릴 유도체
DK3497099T3 (da) *	2016-08-12	2022-05-23	Athenex Inc	Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
WO2018125815A1 (en)	2016-12-29	2018-07-05	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
EP3562818B1 (de)	2016-12-29	2022-05-18	ENYO Pharma	Thiophenederivate als antivirale agenzien
WO2018125817A1 (en)	2016-12-29	2018-07-05	Dow Agrosciences Llc	Processes for the preparation of pesticidal compounds
KR20190115451A (ko)	2017-02-03	2019-10-11	세르타 테라퓨틱스 피티와이 엘티디.	항-섬유성 화합물
MA49014A (fr)	2017-03-21	2020-02-05	Arbutus Biopharma Corp	Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
AU2018255413A1 (en)	2017-04-20	2019-12-05	Leidos Biomedical Research, Inc.	K-Ras modulators
CN111727042A (zh)	2017-12-06	2020-09-29	仁新医药私人有限公司	微管蛋白抑制剂
WO2019148244A1 (en) *	2018-02-01	2019-08-08	The University Of Sydney	Anti-cancer compounds
EP3774768A4 (de) *	2018-04-04	2022-01-05	Aurigene Discovery Technologies Limited	Substituierte pyrazolderivate als selektive cdk12/13-inhibitoren
WO2020142559A1 (en)	2018-12-31	2020-07-09	Biomea Fusion, Llc	Inhibitors of menin-mll interaction
SG11202106304RA (en)	2018-12-31	2021-07-29	Biomea Fusion Llc	Irreversible inhibitors of menin-mll interaction
CN111793034B (zh) *	2020-07-24	2021-11-19	华中科技大学	苯并咪唑盐衍生物与制备抗肿瘤药物的应用
CA3194868A1 (en) *	2020-10-16	2022-04-21	Georg Winter	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
TW202229268A (zh) *	2020-12-22	2022-08-01	大陸商上海拓界生物醫藥科技有限公司	Ｃｄｋ２抑制劑及其製備方法
WO2023107714A2 (en) *	2021-12-10	2023-06-15	Prothena Biosciences Limited	Methods for treating neurological disorders
WO2023203172A1 (en) *	2022-04-20	2023-10-26	Proxygen Gmbh	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162360A (en)	1991-06-24	1992-11-10	Warner-Lambert Company	2-heteroatom containing urea and thiourea ACAT inhibitors
CA2203517A1 (en)	1994-11-10	1996-05-23	Alan M. Laibelman	Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US6043246A (en)	1996-12-03	2000-03-28	Banyu Pharmaceutical Co., Ltd.	Urea derivatives
US6087381A (en)	1997-05-22	2000-07-11	G. D. Searle & Company	Pyrazole derivatives as p38 kinase inhibitors
ES2155045T3 (es) *	1997-12-22	2007-02-01	Bayer Pharmaceuticals Corp.	Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
JP4403482B2 (ja)	1997-12-22	2010-01-27	バイエルコーポレイション	置換複素環尿素合成のための中間体およびその製造方法
CN1373662A (zh) *	1999-08-12	2002-10-09	法玛西雅意大利公司	3(5)－氨基－吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途
US6455559B1 (en) *	2001-07-19	2002-09-24	Pharmacia Italia S.P.A.	Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents

2000
- 2000-05-05 CN CN00812732A patent/CN1373662A/zh active Pending
- 2000-05-05 PL PL00353455A patent/PL353455A1/xx not_active Application Discontinuation
- 2000-05-05 IL IL14792300A patent/IL147923A0/xx unknown
- 2000-05-05 HU HU0203542A patent/HUP0203542A3/hu unknown
- 2000-05-05 BR BR0013143-1A patent/BR0013143A/pt not_active Application Discontinuation
- 2000-05-05 AU AU49714/00A patent/AU4971400A/en not_active Abandoned
- 2000-05-05 EE EEP200200065A patent/EE200200065A/xx unknown
- 2000-05-05 WO PCT/US2000/006699 patent/WO2001012189A1/en active IP Right Grant
- 2000-05-05 ES ES00931906T patent/ES2249270T3/es not_active Expired - Lifetime
- 2000-05-05 US US10/048,486 patent/US7034049B1/en not_active Expired - Fee Related
- 2000-05-05 KR KR1020027001857A patent/KR20020060160A/ko not_active Application Discontinuation
- 2000-05-05 EP EP00931906A patent/EP1202733B1/de not_active Expired - Lifetime
- 2000-05-05 YU YU9602A patent/YU9602A/sh unknown
- 2000-05-05 OA OA1200200051A patent/OA12046A/en unknown
- 2000-05-05 SK SK181-2002A patent/SK1812002A3/sk unknown
- 2000-05-05 JP JP2001516535A patent/JP2003507329A/ja not_active Withdrawn
- 2000-05-05 AP APAP/P/2002/002442A patent/AP2002002442A0/en unknown
- 2000-05-05 AT AT00931906T patent/ATE305782T1/de not_active IP Right Cessation
- 2000-05-05 GE GE4758A patent/GEP20053476B/en unknown
- 2000-05-05 DK DK00931906T patent/DK1202733T3/da active
- 2000-05-05 CA CA002383555A patent/CA2383555C/en not_active Expired - Fee Related
- 2000-05-05 DE DE60023012T patent/DE60023012T2/de not_active Expired - Fee Related
- 2000-05-05 CZ CZ2002422A patent/CZ2002422A3/cs unknown
- 2000-05-05 EA EA200200248A patent/EA005373B1/ru not_active IP Right Cessation
- 2000-05-05 NZ NZ517237A patent/NZ517237A/xx unknown
- 2000-05-05 MX MXPA02001498A patent/MXPA02001498A/es active IP Right Grant
- 2000-05-15 PE PE2000000453A patent/PE20010130A1/es not_active Application Discontinuation
- 2000-05-16 AR ARP000102347A patent/AR026122A1/es unknown
- 2000-09-22 US US09/667,603 patent/US6218418B1/en not_active Expired - Fee Related
2002
- 2002-02-11 NO NO20020684A patent/NO20020684L/no not_active Application Discontinuation
- 2002-02-11 IS IS6265A patent/IS6265A/is unknown
- 2002-02-12 HR HR20020128A patent/HRP20020128A2/hr not_active Application Discontinuation
- 2002-02-22 ZA ZA200201511A patent/ZA200201511B/xx unknown
- 2002-03-05 BG BG06480A patent/BG106480A/xx unknown
- 2002-03-11 MA MA26549A patent/MA25493A1/fr unknown
- 2002-11-26 HK HK02108532.6A patent/HK1046866A1/zh unknown

Also Published As

Publication number	Publication date
IL147923A0 (en)	2002-08-14
KR20020060160A (ko)	2002-07-16
EP1202733A4 (de)	2003-05-14
AP2002002442A0 (en)	2002-03-31
IS6265A (is)	2002-02-11
EA200200248A1 (ru)	2002-08-29
EE200200065A (et)	2003-04-15
ATE305782T1 (de)	2005-10-15
AU4971400A (en)	2001-03-13
SK1812002A3 (en)	2003-02-04
HK1046866A1 (zh)	2003-01-30
PL353455A1 (en)	2003-11-17
BG106480A (en)	2002-09-30
CA2383555C (en)	2009-02-17
CZ2002422A3 (cs)	2002-11-13
ES2249270T3 (es)	2006-04-01
CA2383555A1 (en)	2001-02-22
DE60023012T2 (de)	2006-07-20
NO20020684L (no)	2002-04-03
HRP20020128A2 (en)	2003-04-30
BR0013143A (pt)	2002-06-11
GEP20053476B (en)	2005-03-25
EP1202733A1 (de)	2002-05-08
WO2001012189A1 (en)	2001-02-22
US6218418B1 (en)	2001-04-17
HUP0203542A2 (en)	2003-05-28
YU9602A (sh)	2004-11-25
MXPA02001498A (es)	2003-07-21
HUP0203542A3 (en)	2003-07-28
PE20010130A1 (es)	2001-02-01
NZ517237A (en)	2004-02-27
US7034049B1 (en)	2006-04-25
WO2001012189A8 (en)	2001-08-02
OA12046A (en)	2006-05-02
MA25493A1 (fr)	2002-07-01
CN1373662A (zh)	2002-10-09
EP1202733B1 (de)	2005-10-05
DE60023012D1 (de)	2006-02-16
AR026122A1 (es)	2003-01-29
DK1202733T3 (da)	2005-10-31
EA005373B1 (ru)	2005-02-24
NO20020684D0 (no)	2002-02-11
JP2003507329A (ja)	2003-02-25

Publication	Publication Date	Title
ZA200201511B (en)	2003-05-28	3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
MXPA02001497A (es)	2003-07-21	Derivados de 3-(5)-ureido-pirazol, procedimiento para su preparacion y sus uso como agentes antitumorales.
HUP0201225A3 (en)	2003-11-28	4,5,6,7-tetrahydroindazole derivatives as antitumor agent and process for their preparation
PL347506A1 (en)	2002-04-08	2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
PL347505A1 (en)	2002-04-08	2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
MXPA02001508A (es)	2003-07-21	Derivados de arilmetil-carbonilamino-tiazol y sus usos como agentes antitumorales.
HK1068336A1 (en)	2005-04-29	Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
HUP0004747A3 (en)	2002-12-28	4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation
HK1041482A1 (en)	2002-07-12	Naphtho-and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents.
ZA973883B (en)	1997-12-08	Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents.
ZA200001746B (en)	2000-12-06	3-amino-3-arylpropan-1-ol derivatives, and their preparation and use.
MXPA03006478A (es)	2003-09-22	Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales.
IL139023A0 (en)	2001-11-25	Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
HUP0204572A3 (en)	2004-07-28	Substituierte bisindolylmaleinimide derivatives, process for their preparation and use and pharmaceutcial compositions containing them
ZA200001747B (en)	2000-10-26	3-Amino-3-arylpropan-1-ol derivatives, their preparation and use.
HUP0102518A3 (en)	2002-12-28	5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them
IL146810A0 (en)	2002-07-25	Process for preparing 10, 11-methanobenzosuberane derivatives
HK1052709A1 (en)	2003-11-21	Pluraflavins and derivatives thereof, process for their preparation and use thereof pluraflavin.
GB2350361B (en)	2003-12-03	3,4,5-tricyanophenyl derivatives
SI1406899T1 (sl)	2007-08-31	Derivati fenilacetamido-tiazola, postopek za njihovo pripravo in njihova uporaba kot antitumorska sredstva
ZA988189B (en)	2000-01-10	New imidazotriazolopyrimidines, processes for preparing them and their use as pharmaceutical compositions.
SI1165596T1 (en)	2002-12-31	14,15-alpha-methylene equilenine derivatives, methods for producing the same and medicaments containing them